To appraise the clinical and cost-effectiveness of Pemigatinib within its marketing authorisation for cholangiocarcinoma.
 
Status In progress
Process STA 2018
ID number 3740

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd

Consultees

Companies sponsors Incyte (pemigatinib)
Others Department of Health and Social Care
  NHS Bolton CCG
  NHS England
  NHS Warwickshire North CCG
  Welsh Government
Patient carer groups AMMF – The Cholangiocarcinoma Charity
  Black Health Agency
  Cancer Black Care
  Cancer Equality
  Cancer52
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Anaesthetists
  Association of Cancer Physicians
  Association of Surgeons of Great Britain and Ireland
  Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland
  British Association of Surgical Oncology
  British Geriatric Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Society of Gastroenterology
  British Society of Interventional Radiology
  Cancer Research UK
  Cholangiocarcinoma-UK
  Primary Care Society for Gastroenterology
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Oncology Nursing Society

Commentators

Associated guideline groups National Guideline Alliance
Associated public health groups Public Health England
  Public Health Wales
Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Scottish Society of Gastroenterology
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Upper Gastrointestinal and Pancreatic Diseases Group
  Genomics England
  Guts UK
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
05 June 2020 Invitation to participate
27 March 2020 - 28 April 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
29 January 2020 In progress. Topic is in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance